



STUDY REPORT

Study Title

ASTM E1052
Standard Test Method to Assess the Activity of Microbicides against Viruses in Suspension

Product Identity

Manita Q

Test Microorganism

Human coronavirus, Strain 229E, ATCC VR-740

Study Identification Number

NG16082

Author

Madhuri Patil, B.S.

Study Completion Date

21SEP2020

Testing Facility

Microchem Laboratory
1304 W. Industrial Blvd.
Round Rock, Texas 78681

Study Sponsor

PRODECA Global, LLC
Christian Sanchez / Baltasar Alvarez
5434 Randwick Trail
Frisco, TX 75036



STUDY REPORT SUMMARY

General Study Information

Study Title: ASTM E1052
Standard Test Method to Assess the Activity of
Microbicides against Viruses in Suspension

Study Identification Number: NG16082

Test System

Test Microorganism: Human coronavirus, Strain 229E, ATCC VR-740

Host Cell: MRC-5 (ATCC CCL-171)

Test Substance: Manita Q

Test Substance Receipt Date: 07JUL2020

Test Parameters

Test Substance Dilution: Ready to use liquid test substance

Total Organic Soil Load: No supplementation of organic soil load incorporated
into the test inoculum

Number of Replicates Per
Lot: Single

Contact Time: 30 seconds

Exposure Temperature: Room temperature (24.1°C) and 46% Relative
Humidity (RH)

Neutralization Method: Dilution method: fetal bovine serum (FBS)

Study Dates

Experimental Start Date/Time: 04SEP2020 / 1541

Experimental Termination Date/Time: 11SEP2020 / 1120

Study Completion Date: 21SEP2020



TEST PROCEDURE

Summary

- Stock virus was thawed and was not supplemented with an organic soil load.
- Test and virus control substances were dispensed in 9-part equivalent volumes into sterile vessels.
- Test and virus control substances were each inoculated with 1-part equivalent volumes of the test virus.
- The test suspensions were held for the contact time specified by the Study Sponsor, and then neutralized by ten-fold serial dilutions into the appropriate solution.
- The virus control suspension was neutralized in the same manner as the test suspensions.
- Following neutralization, the viral suspensions were quantified to determine the levels of infectious virus using standard cell culture (e.g. TCID₅₀) assay techniques.
- The cell culture plates were incubated for the period most suitable for the virus-host cell system (e.g. ~7 days).
- After the incubation period, the assay was scored for the presence/absence of test virus and cytotoxic effects. The appropriate calculations were performed (e.g. Spearman-Kärber) to determine viral titers and levels of test substance cytotoxicity, where applicable.
- Log₁₀ and percent reductions were computed for test suspensions relative to the control suspensions, and reported to the Study Sponsor.
- Unless otherwise noted, no modifications to the method were made for this study.

SUCCESS CRITERIA

The following measures are met to ensure the acceptability of virucidal efficacy data:

- The virus titer control demonstrate obvious and or typical cytopathic effects on the monolayers unless a detection method other than cytopathic effect is used.
- Neutralization of the test substance with a low titer (e.g. 1000-5000 infective units) of the test virus is demonstrated.
- Quantification of the test and control parameters are conducted at a minimum of four determinations per dilution.

The product performance criteria follows:

- The log and percent reduction of the test virus following exposure to the test substance are calculated however, there is no minimum reduction level to qualify as “passing” or an “efficacious” product.



CALCULATIONS AND STATISTICAL ANALYSIS

The TCID₅₀ (Tissue Culture Infectivity Dose) represents the endpoint dilution where 50% of the cell cultures exhibit cytopathic effects due to infection by the test virus. The endpoint dilution at which 50% of the host cell monolayers exhibit cytotoxicity is termed the Tissue Culture Dose (TCD₅₀). The TCID₅₀, and TCD₅₀ was determined using the Spearman-Kärber method and calculated as follows:

$$\text{Negative logarithm of endpoint titer} = \frac{[-\text{Log of first dilution inoculated}] - [((\text{sum of \% mortality at each dilution}/100) - 0.5) \times \text{Logarithm of dilution}]}{0.5}$$

The result of this calculation is expressed as TCID₅₀/0.1 ml (or volume of dilution inoculated) for the test, virus control, and neutralization control and TCD₅₀/0.1 ml (or volume of dilution inoculated) for the cytotoxicity control.

Calculation of the Log Reduction

The log reduction in viral titer was calculated as follows:

$$\text{Plate Recovery Control Log}_{10} \text{ TCID}_{50} - \text{Virus-Test Substance Log}_{10} \text{ TCID}_{50}$$

Calculation of the Percent Reduction

The percent reduction in viral titer was calculated as follows:

Percent Reduction = 1 - (C/B) x 100, where:

B = Average TCID₅₀ of virus in control suspensions.

C = Average TCID₅₀ of virus in virus-test suspensions.

The presence of any test substance cytotoxicity were taken into account when calculating the log and percent reductions in viral titer.

If multiple virus control and test replicates were performed, the average TCID₅₀ of each parameter was calculated and the average result used to calculate the log reductions in viral titer.



RESULTS

Table 1: Virus Titer and Virus Control Results

		Virus Titer	Virus Control
Cell Control		0 0 0 0	0 0 0 0
Dilution	10 ⁻¹	N/A	N/A
	10 ⁻²	++++	++++
	10 ⁻³	++++	++++
	10 ⁻⁴	++++	++++
	10 ⁻⁵	++++	++++
	10 ⁻⁶	++++	0++0
	10 ⁻⁷	+0++	0000
	10 ⁻⁸	0000	0000
	TCID ₅₀ per 0.1 ml		7.25 Log ₁₀

Key: + = Virus recovered; 0 = Virus not recovered and/or no cytotoxicity observed;
 T = Cytotoxicity observed; N/A = not applicable

Table 2: Test Results

		Test Results Manita Q
Cell Control		0 0 0 0
Dilution	10 ⁻¹	N/A
	10 ⁻²	TTTT
	10 ⁻³	TTTT
	10 ⁻⁴	0000
	10 ⁻⁵	0000
	10 ⁻⁶	0000
	10 ⁻⁷	0000
	10 ⁻⁸	0000
	TCID ₅₀ per 0.1 ml	
Log Reduction		≥2.50 Log ₁₀
Percent Reduction		≥99.68%

Key: + = Virus recovered; 0 = Virus not recovered and/or no cytotoxicity observed;
 T = Cytotoxicity observed; N/A = not applicable;
 †Taking cytotoxicity and neutralization controls into account.



RESULTS (cont)

Table 3: Cytotoxicity Control Results

		Cytotoxicity Control
Cell Control		0 0 0 0
Dilution	10 ⁻¹	N/A
	10 ⁻²	T T T T
	10 ⁻³	T T T T
	10 ⁻⁴	0 0 0 0
TCD ₅₀ per 0.1 ml		3.50 Log ₁₀

Key: + = Virus recovered; 0 = Virus not recovered and/or no cytotoxicity observed;
 T = Cytotoxicity observed; N/A = not applicable

Table 4: Test Substance Neutralization Control Results

		Neutralization Control
Cell Control		0 0 0 0
Dilution	10 ⁻¹	N/A
	10 ⁻²	T T T T
	10 ⁻³	T T T T
	10 ⁻⁴	+ + + +
Neutralized at TCID ₅₀ per 0.1 ml		3.50 Log ₁₀

Key: + = Virus recovered; 0 = Virus not recovered and/or no cytotoxicity observed;
 T = Cytotoxicity observed; N/A = not applicable



STUDY CONCLUSION

The purpose of the study was to determine the virucidal efficacy of Manita Q against Human coronavirus, Strain 229E, with no supplementation of organic soil load incorporated into the test inoculum, at a contact time of 30 seconds and at room temperature (24.1°C and 46% RH).

The Virus Control demonstrated an average viral titer of 6.00 Log₁₀ TCID₅₀ per 0.1 ml.

Taking the cytotoxicity and neutralization control results into consideration, the evaluated test substance, Manita Q, demonstrated a ≥2.50 Log₁₀ reduction (≥99.68%) in viral titer.

Test substance cytotoxic effects to the host monolayer were observed at 3.50 Log₁₀ TCD₅₀ per 0.1 ml.

The Test Substance Neutralization Control demonstrated that the test substance was neutralized at 3.50 Log₁₀ for the lot assayed.

The test substance will be disposed of 30 days after the completion of this study, unless otherwise requested by the Study Sponsor.

The results of this study apply to the tested substances(s) only. Extrapolation of findings to related materials is the responsibility of the Sponsor.

Copyright © Microchem Laboratory, 2020. Reproduction and ordinary use of this study report by the entity listed as "Sponsor" is permitted. Other copying and reproduction of all or part of this document by other entities is expressly prohibited, unless prior permission is granted in writing by Microchem Laboratory.